Cerebrolysin
Support brain repair with a multi-peptide neurotrophic complex.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About Cerebrolysin
Cerebrolysin is a multi-peptide neurotrophic complex derived from porcine brain proteins. It contains a mixture of low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier. It has been studied extensively for neurodegenerative conditions and traumatic brain injury, with evidence supporting neuronal sprouting, synaptogenesis, and neurogenesis.
Key Benefits
- Multi-peptide complex crossing blood-brain barrier
- Promotes neuronal sprouting/synaptogenesis in preclinical models
- Studied in many stroke & dementia RCTs (evidence weak/mixed)
- Approved in several countries; not FDA-approved in the US
Set a goal (top of the page) to see how Cerebrolysin scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Dizziness
- Headache
- Injection site pain
- Mild agitation
- Nausea
- Sweating
Legal & Regulatory Status
Prescription required in many countries. Not FDA-approved in the US. Approved in Europe, Asia, and Russia. Trial evidence is graded weak/mixed.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- Cochrane review: cerebrolysin for vascular dementia (PMID 23440834)
- Meta-analysis: cerebrolysin for acute ischemic stroke (PMID 28656143)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.